为患有低风险甲状腺癌的患者开发决策辅助:对患者和临床医生的反进行混合方法分析
Christine J O'Neill1,2,3, Ahmad Alam1, Michelle Chapman1
1Surgical Services, John Hunter Hospital, Newcastle, New South Wales, Australia.
World journal of surgery
|August 30, 2025
概括
支持低风险甲状腺癌患者的共同决策 (SDM),改善治疗选择和满意度. 这种工具有助于做出复杂的外科决定.
科学领域:
- 内分泌学
- 外科瘤学
- 关于健康的信息
背景情况:
- 在低风险甲状腺癌治疗中,指南驱动的降级增加了决策的复杂性.
- 分享决策 (SDM) 对患者满意度和护理标准至关重要.
- 目前用于甲状腺癌的患者决策辅助工具 (DA) 不足.
研究的目的:
- 开发和完善一种混合纸张和网络的患者决策辅助 (DA).
- 促进在低风险甲状腺癌中进行手术的共享决策.
- 提高患者对治疗决定的理解和满意度.
主要方法:
- 涉及临床医生,行为科学家,护士和消费者的混合 DA 的代开发.
- 从全国范围的临床咨询和患者测试中获得的混合方法反 (太华尺度,重点小组).
- 根据患者和临床医生的反进行了三次改进.
主要成果:
- 患者发现DA是有用和充足的,报告了较低的决策冲突.
- 临床医生表示愿意使用DA,并解决了对整合的担忧.
- 这种混合式的 DA 改进了视觉吸引力,可读性和最小的情感反应.
结论:
- 在低风险的甲状腺癌患者中进行测试.
- 这项研究旨在提高SDM的外科效果.
- 这种工具支持在治疗甲状腺癌的复杂决策中做出明智的选择.
更多相关视频
相关概念视频
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174


